[A25-109] Daratumumab (smouldering multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Last updated 19.02.2026
Project no.:
A25-109
Commission:
Commission awarded on 18.08.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with smouldering multiple myeloma who are at high risk of developing multiple myeloma
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-109
Federal Joint Committee (G-BA)
19-02-2026 A G-BA decision was published.
G-BA documents on this decision